Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Brooks

Showing results (1101-1110 of 1,175) with videos related to

Pageof 118
Sort By:
Blood|February 21, 2013
Impaired T-cell responses to sphingosine-1-phosphate in HIV-1 infected lymph nodesJoseph C Mudd, Patrick Murphy, Maura Manion, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2020
17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) CohortDaniel W Lin, Yingye Zheng, Jesse K McKenney, et al.
Journal of the National Cancer Institute|May 19, 2017
Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE StudyMark E Robson, Anne S Reiner, Jennifer D Brooks, et al.
Pathology, Research and Practice|December 16, 2023
P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancerMark Bates, Dorinda Mullen, Eimear Lee, et al.
Scientific Data|August 8, 2024
Reinterpretation of prostate cancer pathology by Appl1, Sortilin and Syndecan-1 biomarkersJessica M Logan, Carmela Martini, Alexandra Sorvina, et al.
Cancer Medicine|November 21, 2022
Factors that influence treatment decisions: A qualitative study of racially and ethnically diverse patients with low- and very-low risk prostate cancerAlice Guan, Janet K Shim, Laura Allen, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 15, 2020
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1En-Chi Hsu, Meghan A Rice, Abel Bermudez, et al.
The Journal of Urology|April 30, 2025
Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance StudyMeera R Chappidi, Lisa F Newcomb, Yingye Zheng, et al.
Cancer|September 13, 2021
Treatment in the absence of disease reclassification among men on active surveillance for prostate cancerPeter S Kirk, Kehao Zhu, Yingye Zheng, et al.
The Journal of Urology|July 13, 2022
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active SurveillanceChristopher P Filson, Kehao Zhu, Yijian Huang, et al.
Pageof 118

Showing results (1101-1110 of 1,175) with videos related to

Sort By:
Pageof 118
Blood|February 21, 2013
Impaired T-cell responses to sphingosine-1-phosphate in HIV-1 infected lymph nodesJoseph C Mudd, Patrick Murphy, Maura Manion, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2020
17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) CohortDaniel W Lin, Yingye Zheng, Jesse K McKenney, et al.
Journal of the National Cancer Institute|May 19, 2017
Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE StudyMark E Robson, Anne S Reiner, Jennifer D Brooks, et al.
Pathology, Research and Practice|December 16, 2023
P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancerMark Bates, Dorinda Mullen, Eimear Lee, et al.
Scientific Data|August 8, 2024
Reinterpretation of prostate cancer pathology by Appl1, Sortilin and Syndecan-1 biomarkersJessica M Logan, Carmela Martini, Alexandra Sorvina, et al.
Cancer Medicine|November 21, 2022
Factors that influence treatment decisions: A qualitative study of racially and ethnically diverse patients with low- and very-low risk prostate cancerAlice Guan, Janet K Shim, Laura Allen, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 15, 2020
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1En-Chi Hsu, Meghan A Rice, Abel Bermudez, et al.
The Journal of Urology|April 30, 2025
Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance StudyMeera R Chappidi, Lisa F Newcomb, Yingye Zheng, et al.
Cancer|September 13, 2021
Treatment in the absence of disease reclassification among men on active surveillance for prostate cancerPeter S Kirk, Kehao Zhu, Yingye Zheng, et al.
The Journal of Urology|July 13, 2022
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active SurveillanceChristopher P Filson, Kehao Zhu, Yijian Huang, et al.
Pageof 118